Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 4/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330427 | 0.81 | CHEK1 (0.50) | CHEK1ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL10330434 | 0.78 | CHEK1 (0.45) | CHEK1MAOBALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL10330432 | 0.77 | CHEK1 (0.47) | CHEK1MAOBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10330428 | 0.73 | MAPT (0.50) | CHEK1MAOBALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22386440 | 0.68 | MAPT (0.34) | MAOBTACR1CA12CA9HPGD | |
| SCHEMBL22386453 | 0.68 | MAOB (0.33) | MAOBTACR1CA12CA9HPGD | |
| SCHEMBL10330433 | 0.66 | ALOX5 (0.40) | CHEK1ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL19827143 | 0.65 | CHEK1 (0.42) | CHEK1ALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL23934168 | 0.65 | AR (0.50) | TACR1ALDH1A1MEN1KMT2A | |
| SCHEMBL19821675 | 0.63 | HSP90AA1 (0.43) | CHEK1ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222429-B2 | Photodissociable protective group | National University Corporation NARA Institute of Science and Technology (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222429-B2 | Photodissociable protective group | National University Corporation NARA Institute of Science and Technology (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110028738-A1 | PHOTODISSOCIABLE PROTECTIVE GROUP | National University Corporation NARA Institute of Science and Technology (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20110028738-A1 | PHOTODISSOCIABLE PROTECTIVE GROUP | National University Corporation NARA Institute of Science and Technology (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028738-A1 | PHOTODISSOCIABLE PROTECTIVE GROUP | CRY2, CRY1, APEX1 | CHEK1 1181/4885MAOB 1720/4885TACR1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.